ProKidney posts pooled Phase 2 data showing rilparencel stabilizes kidney function in advanced CKD with diabetes

By Public Technologies
  • ProKidney flagged a new pooled Phase 2 analysis in advanced CKD with type 2 diabetes, with results scheduled for presentation at ASN Kidney Week 2026.
  • The analysis continued to show a favorable safety profile, with signs of kidney function stabilization in patients matching key Phase 3 eligibility criteria.
  • The company also set an oral presentation on non-clinical data supporting a multifactorial rilparencel mechanism tied to tissue repair and reduced injury signaling.
  • Updates add support for the ongoing Phase 3 PROACT 1 study, a key value driver for rilparencel in chronic kidney disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900PRIMZONEFULLFEED9838326) on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.